Literature DB >> 17656480

Risk factors for para-aortic lymph node metastasis of gastric cancer from a randomized controlled trial of JCOG9501.

Eiji Nomura1, Mitsuru Sasako, Seiichiro Yamamoto, Takeshi Sano, Toshimasa Tsujinaka, Taira Kinoshita, Hiroshi Furukawa, Toshio Shimizu, Masahiro Hiratsuka, Osamu Kobayashi, Yukinori Kurokawa, Nobuhiko Tanigawa.   

Abstract

BACKGROUND: No risk factor has been confirmed for para-aortic lymph node (PAN) metastasis from gastric cancer. To identify the risk factors and the most frequent route of metastasis to PAN, we analyzed the prospective data from a phase III trial.
METHODS: In JCOG9501 comparing D2 and D2 + PAN dissection, 260 patients with T2(SS)-T4 gastric cancer underwent radical gastrectomy with PAN dissection. The association between various clinicopathological factors and PAN metastasis was examined.
RESULTS: Macroscopic N stage and tumor size > or = 5 cm were significant risk factors for PAN metastasis after adjusting for other factors. The proportion of PAN metastasis was clearly different between the N0-1 group and the N2-4 group (2.8% versus 20.5%). In the additional multivariate analysis including 17 regional lymph node stations, station No. 7 was the only station with statistical significance (P = 0.002, odds ratio = 41.0).
CONCLUSION: Macroscopic N stage and tumor size were associated with PAN metastasis, and the lymphatics along the left gastric artery seemed to be the most frequent route to the nodes surrounding the aorta. These findings may be useful in predicting PAN metastasis.

Entities:  

Mesh:

Year:  2007        PMID: 17656480     DOI: 10.1093/jjco/hym067

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  8 in total

1.  Lymph node, peritoneal and bone marrow micrometastases in gastric cancer: Their clinical significance.

Authors:  John Griniatsos; Othon Michail; Nikoletta Dimitriou; Ioannis Karavokyros
Journal:  World J Gastrointest Oncol       Date:  2012-02-15

2.  Laparoscopic lymphadenectomy around the left renal vein (16a2lat) by tunneling under the pancreas for advanced Siewert type II adenocarcinoma.

Authors:  Shuji Takiguchi; Yasuhiro Miyazaki; Kohei Murakami; Tomoki Makino; Tsuyoshi Takahashi; Yukinori Kurokawa; Makoto Yamasaki; Kiyokazu Nakajima; Hiroshi Miyata; Masaki Mori; Yuichiro Doki
Journal:  Surg Today       Date:  2015-10-19       Impact factor: 2.549

3.  Impact of body mass index on postoperative outcome of advanced gastric cancer after curative surgery.

Authors:  Yen-Shu Lin; Kuo-Hung Huang; Yuan-Tzu Lan; Wen-Liang Fang; Jen-Hao Chen; Su-Shun Lo; Mao-Chih Hsieh; Anna Fen-Yau Li; Shih-Hwa Chiou; Chew-Wun Wu
Journal:  J Gastrointest Surg       Date:  2013-05-29       Impact factor: 3.452

4.  D2 plus para-aortic lymphadenectomy versus standardized D2 lymphadenectomy in gastric cancer surgery.

Authors:  Jian-Kun Hu; Kun Yang; Bo Zhang; Xin-Zu Chen; Zhi-Xin Chen; Jia-Ping Chen
Journal:  Surg Today       Date:  2009-03-12       Impact factor: 2.549

5.  Routine modified D2 lymphadenectomy performance in pT1-T2N0 gastric cancer.

Authors:  John Griniatsos; Hara Gakiopoulou; Eugenia Yiannakopoulou; Nikoletta Dimitriou; Gerasimos Douridas; Afrodite Nonni; Theodoros Liakakos; Evangelos Felekouras
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

Review 6.  Current status of extended 'D2 plus' lymphadenectomy in advanced gastric cancer.

Authors:  Jing-Quan Li; Donglei He; Yue-Xiang Liang
Journal:  Oncol Lett       Date:  2021-04-12       Impact factor: 2.967

7.  Risk factors of lymph node metastasis in the splenic hilum of gastric cancer patients: a meta-analysis.

Authors:  Jun Du; Yangchao Shen; Wenwu Yan; Jinguo Wang
Journal:  World J Surg Oncol       Date:  2020-09-01       Impact factor: 2.754

Review 8.  Conversion Surgery for Stage IV Gastric Cancer.

Authors:  Fei Zhang; Xuanzhang Huang; Yongxi Song; Peng Gao; Cen Zhou; Zhexu Guo; Jinxin Shi; Zhonghua Wu; Zhenning Wang
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.